An enormous strength of the Fiona and Stanley Druckenmiller Center for Lung Cancer Research is the breadth of world-class expertise of its members.
Our leadership alone represents tremendous translational research talent in lung cancer, collaborating on multidisciplinary research in such areas as:
- genomic characterization of thoracic cancers
- innovations in minimally invasive surgery
- advances in medical therapies
Thoracic surgeon David Jones, Chief of MSK’s Thoracic Service in the Department of Surgery and co-director of the DCLCR, is a pioneer in lung cancer metastasis biology and biomarker development. His research focuses on the biology and regulation of lung cancer metastasis, and his laboratory was the first to identify the importance of the metastasis suppressor gene BRMS1 in lung cancer. Dr. Jones directs a program focused on understanding the mechanisms of lung cancer metastasis and how targeted therapies and small molecule inhibitors may target these processes.
Medical oncologist Charles Rudin, Chief of MSK’s Thoracic Oncology Service and co-director of the DCLCR, is a translational researcher and leader in the study of lung cancer and other thoracic malignancies as well as developmental therapy for advanced solid tumors. He has conducted novel studies using patient-derived tumor tissue for preclinical drug testing and has led comprehensive analyses of genomic alterations in small cell lung cancer. Dr. Rudin directs a broad research program of therapeutic study including laboratory-based treatment discovery and innovative early- and late-phase clinical trials.